EUVIMEDOpdag EUVIMED
Klinische Studie (Phase I)Open access · CC BY-NC-ND 4.0

Phase 1 Evaluation of the Pharmacokinetics of Sevasemten ( EDG ‐5506) for Potential Food Effect and Drug–Drug Interaction With a CYP3A4 Moderate Inhibitor

Molly Madden, Roxana Donisa Dreghici, Jeffrey A Silverman iD

Clinical and Translational Science · 2026-11 · 19 (11)

DOI: 10.1111/cts.70751 ↗

At a glance

Klinische Studie (Phase I) in Clinical and Translational Science, published online on 2026-11-03. Written by Molly Madden and 2 co-authors. Institution: Edgewise Therapeutics, Inc., Boulder, Colorado, USA. Major MEDLINE topics: Cytochrome P-450 CYP3A Inhibitors, Food-Drug Interactions, Verapamil. 12 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Sevasemten (EDG‐5506) is an investigational, small molecule, in development for the treatment of Becker and Duchenne muscular dystrophy. In vitro data suggest sevasemten is a substrate for cytochrome P450 (CYP)3A4. Here, we investigate whether the pharmacokinetics (PK) of sevasemten are affected when co‐administered with a moderate CYP3A4 inhibitor, verapamil. The impact of a high‐fat meal on the PK of sevasemten was also investigated. This Phase 1, open‐label, parallel study of healthy subjects dosed three unique cohorts (sevasemten alone, sevasemten co‐administered with verapamil, and sevasemten under fed conditions). Administration of a single dose of sevasemten with daily dosing of verapamil had no significant effect on the maximum concentration (C max ) or area under the plasma concentration‐time curve (AUC) of sevasemten compared to a single dose of sevasemten under fasted conditions (Geometric mean ratios of 101.6% and 97.5%, respectively), indicating that the PK of sevasemten may not be influenced by verapamil, a moderate CYP3A4 inhibitor. Administration of a single dose of sevasemten under fed conditions increased the AUCs of sevasemten by 20% to 38%, while the C max remained comparable to that under fasted conditions. Together, these data support allowing patients who benefit from sevasemten to also use a moderate CYP3A inhibitor without dose modification and support administration of sevasemten without regard to food intake.

Subjects

MeSH terms (MEDLINE)

Cytochrome P-450 CYP3A InhibitorsFood-Drug InteractionsVerapamilHumansMaleCytochrome P-450 CYP3AArea Under CurveAdultFemaleYoung AdultHealthy VolunteersDrug Interactions

Author keywords

Phase 1drug–drug interactionsmetabolitespharmacokinetics

Substances

Cytochrome P-450 CYP3A InhibitorsVerapamilCytochrome P-450 CYP3ACYP3A4 protein, human

Authors and institutions

  • Edgewise Therapeutics, Inc., Boulder, Colorado, USA.

ORCID profiles: Jeffrey A Silverman

Cite

APA

Madden, M., Dreghici, R. D., & Silverman, J. A. (2026). Phase 1 Evaluation of the Pharmacokinetics of Sevasemten ( EDG ‐5506) for Potential Food Effect and Drug–Drug Interaction With a CYP3A4 Moderate Inhibitor. Clinical and Translational Science, 19(11). https://doi.org/10.1111/cts.70751

Vancouver

Madden M, Dreghici RD, Silverman JA. Phase 1 Evaluation of the Pharmacokinetics of Sevasemten ( EDG ‐5506) for Potential Food Effect and Drug–Drug Interaction With a CYP3A4 Moderate Inhibitor. Clinical and Translational Science. 2026;19(11). doi:10.1111/cts.70751

BibTeX
@article{Madden2026,
  author = {Madden, Molly and Dreghici, Roxana Donisa and Silverman, Jeffrey A},
  title = {Phase 1 Evaluation of the Pharmacokinetics of Sevasemten ( EDG ‐5506) for Potential Food Effect and Drug–Drug Interaction With a CYP3A4 Moderate Inhibitor},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {11},
  doi = {10.1111/cts.70751}
}
Start for free →